ES2531657T3 - Formulación de una proteína - Google Patents

Formulación de una proteína Download PDF

Info

Publication number
ES2531657T3
ES2531657T3 ES12157010.5T ES12157010T ES2531657T3 ES 2531657 T3 ES2531657 T3 ES 2531657T3 ES 12157010 T ES12157010 T ES 12157010T ES 2531657 T3 ES2531657 T3 ES 2531657T3
Authority
ES
Spain
Prior art keywords
composition
formula
ionic strength
protein
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12157010.5T
Other languages
English (en)
Inventor
Jan Jezek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41256085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2531657(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0807929A external-priority patent/GB0807929D0/en
Priority claimed from GB0902472A external-priority patent/GB0902472D0/en
Application filed by Arecor Ltd filed Critical Arecor Ltd
Application granted granted Critical
Publication of ES2531657T3 publication Critical patent/ES2531657T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición acuosa para uso en terapia que comprende una vacuna basada en un polisacárido susceptible de escisión hidrolítica de un resto de polisacárido a partir de una proteína portadora, en donde la fuerza iónica de la composición es menor que 30 mM, siendo dicha fuerza iónica calculada usando la fórmula: **Fórmula** en la que cx es la concentración molar de ion x (mol l-1), zx es el valor absoluto de la carga de ion x y la suma abarca todos los iones (n) presentes en la composición.
ES12157010.5T 2008-05-01 2009-05-01 Formulación de una proteína Active ES2531657T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0807929 2008-05-01
GB0807929A GB0807929D0 (en) 2008-05-01 2008-05-01 Protein formulation
GB0902472 2009-02-13
GB0902472A GB0902472D0 (en) 2009-02-13 2009-02-13 Formulation

Publications (1)

Publication Number Publication Date
ES2531657T3 true ES2531657T3 (es) 2015-03-18

Family

ID=41256085

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12157010.5T Active ES2531657T3 (es) 2008-05-01 2009-05-01 Formulación de una proteína
ES09738438.2T Active ES2519475T5 (es) 2008-05-01 2009-05-01 Formulación de una proteína

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09738438.2T Active ES2519475T5 (es) 2008-05-01 2009-05-01 Formulación de una proteína

Country Status (7)

Country Link
US (1) US9005611B2 (es)
EP (2) EP2283027B2 (es)
JP (1) JP2011519848A (es)
CN (1) CN102066401A (es)
CA (1) CA2726824A1 (es)
ES (2) ES2531657T3 (es)
WO (1) WO2009133408A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5859987B2 (ja) * 2010-02-24 2016-02-16 アレコー リミテッド タンパク質製剤
JP2014214153A (ja) * 2013-04-30 2014-11-17 ニプロ株式会社 水溶液製剤およびその製造方法
GB201607918D0 (en) * 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051627A (en) 1960-08-18 1962-08-28 Armour Pharma Stabilized chymotrypsin solution
CA1187388A (en) 1978-09-20 1985-05-21 American Monitor Corporation Stabilization of working reagent solutions containing nadh, nadph, and/or enzymes, and the use of such stabilized reagents in enzymes or substrate assays
US4983513A (en) 1986-03-28 1991-01-08 Beckman Instruments, Inc. Sulfhydryl compounds for suppressing the inhibitory effects of NAD degradation products on LD-L activity
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
IT1247946B (it) 1991-05-17 1995-01-05 Instrumentation Lab Srl Stabilizzazione in forma liquida dell'enzima urato ossidasi
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE69729880T3 (de) 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
JP3723857B2 (ja) † 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
SE9900496D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
JP2002125693A (ja) 2000-10-19 2002-05-08 Toyobo Co Ltd 無細胞タンパク質合成用細胞抽出液組成物
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
US7027969B2 (en) 2001-08-30 2006-04-11 Board Of Regents, The University Of Texas System Ensemble-based analysis of the pH-dependence of stability of proteins
GB0202633D0 (en) 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
US20040091490A1 (en) 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
JP2007500243A (ja) 2003-06-09 2007-01-11 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 成長ホルモンの増進された経粘膜送達のための組成物および方法
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
WO2006094764A1 (en) * 2005-03-07 2006-09-14 Mondobiotech Licensing Out Ag Formulation for aviptadil
EP2264162A1 (en) * 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
US20090136538A1 (en) 2006-05-22 2009-05-28 Jan Jezek Stable vaccine formulation
WO2008066322A1 (en) 2006-11-28 2008-06-05 Daewoong Co., Ltd. A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
EP2341940A1 (en) 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein

Also Published As

Publication number Publication date
EP2457590A2 (en) 2012-05-30
WO2009133408A3 (en) 2011-04-07
ES2519475T5 (es) 2018-07-02
CN102066401A (zh) 2011-05-18
US20110097348A1 (en) 2011-04-28
US9005611B2 (en) 2015-04-14
EP2283027B1 (en) 2014-08-13
EP2457590A3 (en) 2012-06-27
CA2726824A1 (en) 2009-11-05
EP2283027A2 (en) 2011-02-16
ES2519475T3 (es) 2014-11-07
WO2009133408A2 (en) 2009-11-05
JP2011519848A (ja) 2011-07-14
EP2283027B2 (en) 2018-04-18
EP2457590B1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
MX358716B (es) Composiciones estables para el cuidado bucal que comprenden un aminoácido básico , una sal de estroncio y una fuente de ion fluoruro y usos de las mismas.
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
UY33802A (es) Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja
NI201200152A (es) Formulaciones de insulina de acción prolongada.
MX344840B (es) Producto de cuidado oral y metodos de uso y fabricación de los mismos.
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
EA201100030A1 (ru) Пиразольные соединения 436
CR20110424A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
CL2008003684A1 (es) Composicion farmaceutica que comprende una sal de aluminio, que tiene una relacion molar de aluminio a cloruro de 0,3:1 a 3:1 aproximadamente, ademas comprende zirconio; metodo de preparacion de la composicion; uso como antitranspirante.
MY150547A (en) Protein kinase inhibitors
EA201490200A1 (ru) 4-(8-метокси-1-((1-метоксипропан-2-ил)-2-(тетрагидро-2-н-пиран-4-ил)-1н-имидазо[4,5-c]хинолин-7-ил)-3,5-диметилизоксазол и его применение в качестве ингибитора бромодомена
BR112012015255A2 (pt) "anticorpo, composição farmaceutica, uso de um anticorpo,método de tramento ,ácido nucleico, vetor de espressão, célula hospedeira e método de produção de um anticorpo recobinante"
EA201170983A1 (ru) Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии
BRPI0512108A (pt) antibióticos contendo complexos de ácido borìnico e métodos de uso
UA105229C2 (uk) Фармацевтичний склад
ES2531093T3 (es) Procedimiento de preparación de halogenuros de N-alquil-naltrexona
ECSP088532A (es) Formulación de suspensión de fexofenadina
NZ593524A (en) A nonapeptide with anti-tumour activity
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
CL2013001935A1 (es) Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer.
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
BR112013011562C8 (pt) enxágue bucal e método cosmético para melhorar a saúde oral
AR077371A1 (es) DERIVADOS DE PIRAZOL, SU PREPARACIoN Y SU APLICACIoN EN LA TERAPIA DEL CÁNCER
CY1110213T1 (el) Παραγωγα αζολοπυριδιν-2-ονης ως αναστολεις λιπασων και φωσφολιπασων
AR088398A1 (es) Preparacion de liberacion sostenida